BEGIN:VCALENDAR VERSION:2.0 METHOD:PUBLISH PRODID:-//Telerik Inc.//Sitefinity CMS 13.3//EN BEGIN:VTIMEZONE TZID:GMT Standard Time BEGIN:STANDARD DTSTART:20231002T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=10 TZNAME:GMT Standard Time TZOFFSETFROM:+0100 TZOFFSETTO:+0000 END:STANDARD BEGIN:DAYLIGHT DTSTART:20230301T010000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYHOUR=1;BYMINUTE=0;BYMONTH=3 TZNAME:GMT Daylight Time TZOFFSETFROM:+0000 TZOFFSETTO:+0100 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT DESCRIPTION:Date: \;Thursday 11th June 2020\nTime: \;10:00 - 11:00\ nSpeakers: \;Mike Smith (Pfizer) and Jacquie Christie \;(GSK)  \;\nRegistration:\nThis webinar is part of our 2020 Conference Webinar Ser ies. Further information including details of other webinars that are incl uded in the Conference package can be found \;here.\nMembers \;rec eive all webinars in the conference series for free.\nNon-members \;re ceive all webinars in the conference series for £\;100+VAT\, which in cludes complimentary membership* of PSI until the 31st December 2020.\n\nT o register your place for this event\, and others in the Conference webina r series\, please click here.\n\n\n\nSpeaker Details:\n\n\n\n \n \n \n Speaker\n \n \n Biography\n \n \n Session Abstract\n \n \n \n \n \n M ike Smith\, \n Pfizer\n \n \n Mike K Smith has worked in a variety of roles at Pfizer for over 26 years. He is a currently a Senior Director in Statistics providing specialist co mputation and modelling solutions to projects\, evaluating and deploying n ew tools. He is an RStudio certified tidyverse trainer and a professional R geek. He was previously in a similar role for the pharmacometrics modell ing and simulation group within clinical pharmacology at Pfizer. During th is time he worked on the IMI DDMoRe project\, delivering a novel model des cription language for pharmacometric models. He is the author or collabora tor on many manuscripts pertaining to model-informed drug development\, mo delling and simulation and implementation of tools and workflows to assist with these.\n \n \n What is innovation? How do I innovate? Is it a skill that I can learn or improve on? In this p resentation I will attempt to define what I mean by innovation and break d own what I consider to be drivers of innovation. Some of these are things that you CAN definitely work on. It is true that some are environmental or cultural but even these are things that you can influence or change. I wi ll illustrate how these elements have come together to help me and my coll eagues deliver on projects\, innovate and break out of &ldquo\;tried and t ested&rdquo\; methods\, including those cited in my RSS/PSI Statistical Ex cellence in the Pharmaceutical Industry award.\n \n \n \n \n Jacquie Christie \;\n GSK \n Jacquie Christie has 25 years&rsquo\; experience as a biosta tistician in the pharmaceutical industry.Her current position is Therapeut ic Area Biostatistics Head for Immunology &\; Inflammation\, in which s he has overall responsibility for statistical activities relating to clini cal development\, from phase 1 through to lifecycle management. She has be en in this role for over 10 years\, and in that time has supported numerou s projects in a wide range ofimmune mediated diseases.She has previously h eld roles as Biostatistics Head for Neurology Drug Discovery and for GSK&r squo\;s Biopharmaceuticals unit.\n Quantitative Decision-Making for Clinical Development.\n \n Low productivity and late-stage attrition are well-known pharmaceutical R&\;D problems\; on e cause is poor decision-making at key milestones.Failure to consider the impact of current design choices on future investment options increases un certainty when the decision-point arrives\, and consequently increases the risk of a wrong decision. \;\n This talk will outline an a pproach to quantitative decision-making in a completely Bayesian setting.P rior distributions are used to evaluate proposed study designs and decisio n rules against not only the probability of success of the current study\, but that of the subsequent study or set of studies.Termination and progre ssion criteria and associated risks are then clear\, allowing more informe d decision-making. The approach is applicable to all phases of R&\;D.\n  \;\n \n \n \n\n \; DTEND:20200611T100000Z DTSTAMP:20240329T081409Z DTSTART:20200611T090000Z LOCATION: SEQUENCE:0 SUMMARY:PSI Conference Webinar: PSI/RSS Prize Winners Session UID:RFCALITEM638472968499918436 X-ALT-DESC;FMTTYPE=text/html:
Date: \;Thursday 11th
June 2020
\nTime: \;10:00 - 11:00
\nSpeakers: \;Mike Smith (Pfizer) and Jacquie Christi
e \;(GSK) \;
This webinar is part of our 2020 Conference Webinar Series. Further i
nformation including details of other webinars that are included in the Co
nference package can be found \;here.
\nMembers \;re
ceive all webinars in the conference series for free.
\nNon-m
embers \;receive all webinars in the conference series for &p
ound\;100+VAT\, which includes complimentary membership* of PSI until the
31st December 2020.
\n
\nTo register your place for this event\,
and others in the Conference webinar series\, please click here.
\n
\n
\n Speaker \n | \n \n
| \n \n Session Abstract \n | \n
\n
| \n \n
Mike K Smith has worked in a variety of roles at Pfizer for over 26 years. He is a currently a Senior Director in Statistics providing specia list computation and modelling solutions to projects\, evaluating and depl oying new tools. He is an RStudio certified tidyverse trainer and a profes sional R geek. He was previously in a similar role for the pharmacometrics modelling and simulation group within clinical pharmacology at Pfizer. Du ring this time he worked on the IMI DDMoRe project\, delivering a novel mo del description language for pharmacometric models. He is the author or co llaborator on many manuscripts pertaining to model-informed drug developme nt\, modelling and simulation and implementation of tools and workflows to assist with these. \n | \n \n What is innovation? How do I innova te? Is it a skill that I can learn or improve on? In this presentation I w ill attempt to define what I mean by innovation and break down what I cons ider to be drivers of innovation. Some of these are things that you CAN de finitely work on. It is true that some are environmental or cultural but e ven these are things that you can influence or change. I will illustrate h ow these elements have come together to help me and my colleagues deliver on projects\, innovate and break out of &ldquo\;tried and tested&rdquo\; m ethods\, including those cited in my RSS/PSI Statistical Excellence in the Pharmaceutical Industry award. \n | \n
\n Jacquie Christie \;< /strong> \n GSK | \n Jacquie Christie has 25 years&rsquo\; experience as a biostatistician in the pharmaceutical industry.Her current position i s Therapeutic Area Biostatistics Head for Immunology &\; Inflammation\, in which she has overall responsibility for statistical activities relati ng to clinical development\, from phase 1 through to lifecycle management. She has been in this role for over 10 years\, and in that time has suppor ted numerous projects in a wide range ofimmune mediated diseases.She has p reviously held roles as Biostatistics Head for Neurology Drug Discovery an d for GSK&rsquo\;s Biopharmaceuticals unit. | \nQuantitative Decision-Making for Clini
cal Development. \n \n Low produ ctivity and late-stage attrition are well-known pharmaceutical R&\;D pr oblems\; one cause is poor decision-making at key milestones.Failure to co nsider the impact of current design choices on future investment options i ncreases uncertainty when the decision-point arrives\, and consequently in creases the risk of a wrong decision. \; \n This talk will outline an approach to quantitative decision-making in a completely B ayesian setting.Prior distributions are used to evaluate proposed study de signs and decision rules against not only the probability of success of th e current study\, but that of the subsequent study or set of studies.Termi nation and progression criteria and associated risks are then clear\, allo wing more informed decision-making. The approach is applicable to all phas es of R&\;D. \n  \; \n | \n
 \;
END:VEVENT END:VCALENDAR